Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?-Reference-Cited by-同舟云学术

Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?

Published:2022-11 Issue: Volume:110 Page:102454
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Garufi Giovanna,Carbognin Luisa,Arcanà Concetta,Parola Sara,Ventriglia Anna,Doronzo Antonio,Garutti Mattia,Orlandi Armando,Palazzo Antonella,Fabi Alessandra,Bria Emilio,Tortora Giampaolo,Arpino Grazia,Giuliano Mario,Del Mastro Lucia,De Laurentiis Michelino,Puglisi Fabio

Funder

Airc Italian Foundation for Cancer Research

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference90 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

3. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.

4. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44.

5. Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers (Basel) 2022;14.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications;Cancer Treatment Reviews;2024-11

2. Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer;JAMA Oncology;2024-09-12

3. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer;ESMO Open;2024-07

4. Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy;2024-03-14

5. Development of an obesity-related multi-gene prognostic model incorporating clinical characteristics in luminal breast cancer;iScience;2024-03